| 王 闰,陆春来,王 琦,江 漪,孙建文,孟 慧.碳酸镧咀嚼片联合依降钙素对血液透析高磷血症患者冠状动脉钙化及血磷水平的影响[J].现代生物医学进展英文版,2023,(6):1091-1094. |
| 碳酸镧咀嚼片联合依降钙素对血液透析高磷血症患者冠状动脉钙化及血磷水平的影响 |
| Effect of Lanthanum Carbonate Chewable Tablets Combined with Calcitonin on Coronary Artery Calcification and Blood Phosphorus Level in Patients with Hemodialysis Hyperphosphatemia |
| Received:August 21, 2022 Revised:September 17, 2022 |
| DOI：10.13241/j.cnki.pmb.2023.06.018 |
| 中文关键词: 碳酸镧咀嚼片 依降钙素 血液透析 高磷血症 冠状动脉钙化 血磷 |
| 英文关键词: Lanthanum Carbonate Chewable Tablets Calcitonin Hemodialysis Hyperphosphatemia Coronary Artery Calcification Blood phosphorus |
| 基金项目:上海市自然科学基金项目（17ZR1436432） |
|
| Hits: 939 |
| Download times: 483 |
| 中文摘要: |
| 摘要 目的：观察碳酸镧咀嚼片联合依降钙素对血液透析高磷血症患者冠状动脉钙化及血磷水平的影响。方法：选取2019年8月~2021年3月我院接收的血液透析高磷血症患者120例，采用双色球法，将患者分为对照组（60例，依降钙素治疗）和观察组（60例，在对照组基础上结合碳酸镧咀嚼片治疗），对比两组疗效、血磷、血钙、钙磷乘积、全段甲状旁腺激素（iPTH）、成纤维生长因子23（FGF-23）、冠状动脉钙化积分（CACS），观察两组不良反应发生情况。结果：观察组临床总有效率（91.67%）优于对照组（70.00%）（P<0.05）。两组不良反应发生率组间对比无差异（P>0.05）。观察组治疗结束后血磷、iPTH、血钙、FGF-23、钙磷乘积、CACS低于对照组（P<0.05）。结论：血液透析高磷血症患者采用碳酸镧咀嚼片联合依降钙素治疗，可延缓冠状动脉钙化，有效降低血磷水平，安全有效。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effect of Lanthanum Carbonate Chewable Tablets Combined with calcitonin on coronary artery calcification and blood phosphorus level in patients with hemodialysis hyperphosphatemia. Methods: 120 patients with hemodialysis hyperphosphatemia received by our hospital from August 2019 to March 2021 were selected. The patients were divided into the control group (60 cases, calcitonin treatment) and the observation group (60 cases, Lanthanum Carbonate Chewable Tablets on the basis of the control group treatment) by double color ball method. The curative effects, blood phosphorus, blood calcium, calcium phosphorus product, intact parathyroid hormone (iPTH), fibroblast growth factor 23 (FGF-23) and coronary artery calcification score (CACS) of the two groups were compared, and the adverse reactions of the two groups were observed. Results: The total clinical effective rate of the observation group (91.67%) was better than that of the control group (70.00%) (P<0.05). There was no difference in the incidence of adverse reactions in two groups (P>0.05). After treatment, blood phosphorus, iPTH, blood calcium, FGF-23, calcium phosphorus product and CACS in the observation group were lower than those in the control group (P<0.05). Conclusion: Lanthanum Carbonate Chewable Tablets combined with calcitonin can delay coronary artery calcification and effectively reduce blood phosphorus level in patients with hemodialysis hyperphosphatemia, which is safe and effective. |
|
View Full Text
View/Add Comment Download reader |
| Close |
